南卡罗来纳州 的 伯基特淋巴瘤 临床试验
南卡罗来纳州 有 5 项针对 伯基特淋巴瘤 的研究正在招募参与者。
南卡罗来纳州 的城市
官方研究文本（英文）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
招募中2 期
366 Days – 46 Years · 所有性别 · 更新于 2026年10月2日 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Prisma Health Richland Hospital, Columbia
- Prisma Health Cancer Institute - Easley, Easley
- 以及另外 8 项
招募中3 期
18 至 39 岁 · 所有性别 · 更新于 2026年10月2日 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
招募中2 期
365 Days · 所有性别 · 更新于 2026年9月25日 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
招募中2 期
1 至 30 岁 · 所有性别 · 更新于 2026年9月1日 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Medical University of South Carolina, Charleston
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
招募中3 期
365 Days – 25 Years · 所有性别 · 更新于 2026年8月25日 · NCT03959085数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。